Journey Medical (DERM) EV to EBIT (2021 - 2026)

Journey Medical (DERM) has reported EV to EBIT for 6 consecutive years, with 370.64 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to EBIT rose 825.5% year-over-year to 370.64; the trailing twelve-month figure through Jun 2026 stood at 56.19 (down 162.34% YoY), and the FY2025 full-year result was 17.0, down 290.24% from the prior year.
• EV to EBIT advanced to 370.64 in Q2 2026 per DERM's latest filing, from 67.59 in the prior quarter.
• Across five years, EV to EBIT topped out at 370.64 in Q2 2026 and bottomed at 313.6 in Q4 2025.
• Historically, EV to EBIT has averaged 16.91 across 5 years, with a median of 17.59 in 2024.
• The sharpest annual moves came in 2023 and 2026: EV to EBIT slumped 22140.83% in 2023, then surged 825.5% in 2026.
• Over 5 years, EV to EBIT stood at 0.17 in 2022, then plunged by 22140.83% to 36.87 in 2023, then surged by 172.33% to 26.67 in 2024, then plunged by 1275.84% to 313.6 in 2025, then soared by 218.19% to 370.64 in 2026.
• According to Business Quant data, EV to EBIT over the past three periods registered 370.64, 67.59, and 313.6 for Q2 2026, Q1 2026, and Q4 2025 respectively.